Latest Conference Articles

September 9th 2023, 1:52pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The incorporation of brentuximab vedotin (Adcetris) into the frontline treatment of patients with Hodgkin lymphoma correlates with superior efficacy, irrespective of PET2 results, suggesting loss of predictive value with the scan.

September 8th 2023, 10:40pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory large B-cell lymphoma, with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

September 8th 2023, 9:58pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

September 8th 2023, 9:54pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

September 8th 2023, 8:04pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Loncastuximab tesirine-lpyl plus rituximab demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma.

September 8th 2023, 7:58pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.

September 8th 2023, 7:34pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.

September 8th 2023, 4:47pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.

September 8th 2023, 2:32pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

September 8th 2023, 2:08pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.

September 8th 2023, 1:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

A retrospective analysis of the Surveillance, Epidemiology, and End Results database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis.

September 7th 2023, 9:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

September 7th 2023, 8:33pm

Society of Hematologic Oncology Annual Meeting (SOHO)

No difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hematopoietic stem cell transplantation in elderly patients over the age of 60 with acute myeloid leukemia in first complete remission.

September 7th 2023, 8:07pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

September 7th 2023, 7:07pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

September 7th 2023, 6:53pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.

September 7th 2023, 6:50pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

September 7th 2023, 6:05pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.

September 7th 2023, 2:54pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.

September 7th 2023, 2:42pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.